A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19
Status:
Completed
Trial end date:
2021-08-10
Target enrollment:
Participant gender:
Summary
Phase Ib, open-label, multicenter, study of NOX66, given rectally to hospitalized patients
with moderate systemic illness due to COVID-19 infection at high risk of developing severe
sepsis / septic shock.